Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD), and orally bioavailable, brain penetrant and highly potent LRRK2 kinase inhibitors are in early stages of clinical testing. Detection of LRRK2 phosphorylation, as well as phosph...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biochem J
Autori principali: Fernández, Belén, Lara Ordóñez, Antonio Jesús, Fdez, Elena, Mutez, Eugénie, Comptdaer, Thomas, Leghay, Coline, Kreisler, Alexandre, Simonin, Clémence, Vandewynckel, Laurine, Defebvre, Luc, Destée, Alain, Bleuse, Séverine, Taymans, Jean-Marc, Chartier-Harlin, Marie-Christine, Hilfiker, Sabine
Natura: Artigo
Lingua:Inglês
Pubblicazione: Portland Press Ltd. 2019
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792036/
https://ncbi.nlm.nih.gov/pubmed/31527116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BCJ20190315
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi